Cited by 608Venous Thromboembolism Diagnosis and ManagementReproductive Health and ContraceptionBlood Coagulation and Thrombosis Mechanisms

Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9

Open access
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., Lokkegaard, E.·2011·BMJ

Abstract

OBJECTIVE: To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose. DESIGN: National historical registry based cohort study. SETTING: Four registries in Denmark. PARTICIPANTS: Non-pregnant Danish women aged 15-49 with no history of thrombotic disease and followed from January 2001 to December 2009. MAIN OUTCOME MEASURES: Relative and absolute risks of first time venous thromboembolism. RESULTS: Within 8,010,290 women years of observation, 4307 first ever venous thromboembolic events were recorded and 4246 included, among which 2847 (67%) events were confirmed as certain. Compared with non-users of hormonal contraception, the relative risk of confirmed venous thromboembolism in users of oral contraceptives containing 30-40 µg ethinylestradiol with levonorgestrel was 2.9 (95% confidence interval 2.2 to 3.8), with desogestrel was 6.6 (5.6 to 7.8), with gestodene was 6.2 (5.6 to 7.0), and with drospirenone was 6.4 (5.4 to 7.5). With users of oral contraceptives with levonorgestrel as reference and after adjusting for length of use, the rate ratio of confirmed venous thromboembolism for users of oral contraceptives with desogestrel was 2.2 (1.7 to 3.0), with gestodene was 2.1 (1.6 to 2.8), and with drospirenone was 2.1 (1.6 to 2.8). The risk of confirmed venous thromboembolism was not increased with use of progestogen only pills or hormone releasing intrauterine devices. If oral contraceptives with desogestrel, gestodene, or drospirenone are anticipated to increase the risk of venous thromboembolism sixfold and those with levonorgestrel threefold, and the absolute risk of venous thromboembolism in current users of the former group is on average 10 per 10,000 women years, then 2000 women would need to shift from using oral contraceptives with desogestrel, gestodene, or drospirenone to those with levonorgestrel to prevent one event of venous thromboembolism in one year. CONCLUSION: After adjustment for length of use, users of oral contraceptives with desogestrel, gestodene, or drospirenone were at least at twice the risk of venous thromboembolism compared with users of oral contraceptives with levonorgestrel.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmj.d6423

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. RESEARCH on 27 June 2023 by guest. Protected by copyright. http://www.bmj.com/ BMJ: first published as 10.1136/bmj.d6423 on 25 October 2011. Downloaded from

Cited by

Sorted by citations

Authors
Lidegaard, O., Nielsen, L. H., Skovlund, C. W., Skjeldestad, F. E., & Lokkegaard, E.
Affiliations
  • University of Copenhagen (DK)
  • UiT The Arctic University of Norway (NO)
Venue
BMJ
Publisher
BMJ
Published
2011-10-25
Volume
343
Issue
oct25 4
Pages
d6423-d6423
ISSN
  • 0007-1447 (ISSN-L)
  • 0959-8138
  • 1468-5833
OpenAlex
W1999011481
Cited by
608
References
28
Citations by year
2026: 28 · 2025: 41 · 2024: 35 · 2023: 28 · 2022: 28 · 2021: 39 · 2020: 38 · 2019: 31 · 2018: 30 · 2017: 39 · 2016: 34 · 2015: 55 · 2014: 65 · 2013: 60 · 2012: 51
FWCI
50.27
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • BMJ (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Aalborg Universitet
  • Aalborg Universitetshospital
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
venous thromboembolism, oral contraceptives, progestogens, estrogen dose, ethinyl estradiol, levonorgestrel, desogestrel, gestodene, drospirenone, progestin-only pills, hormonal intrauterine device, thrombosis risk, women of reproductive age, Denmark
MeSH terms
Adolescent, Adult, Mineralocorticoid Receptor Antagonists, Androstenes, Anticoagulants, Contraceptives, Oral, Denmark, Dose-Response Relationship, Drug, Epidemiologic Methods, Female, Humans, Intrauterine Devices, Medicated, Middle Aged, Norpregnenes, Pregnancy, Time Factors, Cohort Studies, Confounding Factors, Epidemiologic, Levonorgestrel, Desogestrel, Venous Thromboembolism, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review